NASDAQ:MSLE Satellos Bioscience Q4 2025 Earnings Report $6.40 -0.55 (-7.96%) As of 02:00 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Satellos Bioscience EPS ResultsActual EPS-$0.47Consensus EPS -$0.36Beat/MissMissed by -$0.11One Year Ago EPSN/ASatellos Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASatellos Bioscience Announcement DetailsQuarterQ4 2025Date3/27/2026TimeBefore Market OpensConference Call DateFriday, March 27, 2026Conference Call Time8:00AM ETConference Call ResourcesPress ReleaseAnnual Report (40-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseAnnual report(40-F) Satellos Bioscience Earnings HeadlinesSatellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 26, 2026 | americanbankingnews.comSatellos Bioscience (MSLE) Receives a Buy from GuggenheimMay 21, 2026 | theglobeandmail.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…June 3 at 1:00 AM | Paradigm Press (Ad)Satellos Bioscience Inc MSLEMay 21, 2026 | morningstar.comMSatellos Bioscience Inc.: Satellos Reports First Quarter 2026 Financial Results and Highlights Company ProgressMay 15, 2026 | finanznachrichten.deSatellos Bioscience to Showcase DMD Program at April Bloom Burton Healthcare Investor ConferenceApril 9, 2026 | tipranks.comSee More Satellos Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email. Email Address About Satellos BioscienceSatellos Bioscience (NASDAQ:MSLE) is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.View Satellos Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Urban Outfitters Stock Stalls Despite Another Strong QuarterHIVE Earnings Highlight AI Ambitions Beyond Bitcoin MiningMongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared QuarterCredo Technologies Paved a Path to a $300 Price PointFirstCash Turns Pawn Into a Growth Machine Upcoming Earnings Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
